ZYG11B inhibitors are a class of chemical compounds that specifically target and modulate the activity of the ZYG11B protein, which belongs to the family of ZYG11 proteins. These proteins are part of a larger group of E3 ubiquitin ligases, which play a crucial role in the ubiquitin-proteasome system-a highly regulated process that governs protein degradation within the cell. ZYG11B, in particular, is involved in tagging specific substrates for ubiquitination, a process that marks them for proteasomal degradation. The function of ZYG11B is essential in maintaining proper cellular homeostasis by ensuring that proteins are turned over or degraded at appropriate times. Inhibitors of ZYG11B work by interfering with its ability to recognize or bind to its target proteins, thereby affecting the overall balance of protein degradation in cells. This disruption can lead to the accumulation of specific proteins that would normally be marked for degradation.
At the molecular level, ZYG11B inhibitors tend to exhibit high specificity for the binding domains of the ZYG11B protein, effectively blocking its interaction with substrates or cofactors essential for its ubiquitin ligase activity. The structural complexity of these inhibitors is often reflective of their need to target key regulatory regions of the ZYG11B protein, such as the ubiquitin-binding domain or substrate recognition regions. This specificity is important for reducing off-target effects on other members of the ubiquitin ligase family, particularly ZYG11A, which shares significant structural similarities. The inhibition of ZYG11B, and its subsequent impact on protein degradation pathways, can provide insights into fundamental cellular mechanisms, such as cell cycle regulation, protein quality control, and cellular response to stress, which are critically dependent on tightly controlled protein turnover processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
May inhibit proteasomal activity, potentially affecting the degradation processes in which ZYG11B is involved. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Could inhibit the proteasome, possibly affecting the function of E3 ubiquitin ligases like the one involving ZYG11B. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Potentially inhibits proteasome activity, which might influence the role of ZYG11B in protein degradation. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Might influence p53 pathways, potentially affecting cell cycle processes where ZYG11B is involved. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
Could inhibit neddylation, potentially affecting cullin-RING ligases and influencing ZYG11B function. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
An inhibitor of the proteasome, which could affect the function of ZYG11B in protein degradation pathways. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $66.00 $101.00 $143.00 | 85 | |
May crosslink DNA, potentially affecting cell cycle regulation and the function of ZYG11B. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Could cause DNA damage, potentially affecting cell cycle regulation where ZYG11B might be involved. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
May incorporate into RNA and disrupt processing, potentially influencing ZYG11B-related cell cycle regulation. | ||||||
2′-Deoxy-2′,2′-difluorocytidine | 95058-81-4 | sc-275523 sc-275523A | 1 g 5 g | $56.00 $128.00 | ||
Could inhibit DNA synthesis, potentially affecting cell cycle processes where ZYG11B operates. | ||||||